Septerna, Inc.
NASDAQ:SEPNBiotechnology
-$0.73 today
- Market cap
- $1.88B
- Beta
- 2.38
- P/E (TTM)
- -43.6
- EPS (TTM)
- -$0.81
Volume 0.30M
Average 0.32M
SEPN Common Stock
The par or stated value of issued common shares, plus paid-in capital where reported together.
Septerna, Inc.NASDAQ: SEPN
Common Stock · Q3 FY2026 · quarter ended Sep 2026
Common stock rises 4.4% from a year ago
Common stock stood at $47K at the end of Q3 FY2026, up 4.4% from a year earlier and up 2.2% from the prior quarter. Over 3 fiscal years it compounded at +146.6% a year.
Context
- Common stock amounted to 0.0% of total assets at the end of Q3 FY2026, unchanged from a year earlier.
- Common stock increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether common stock keeps rising in the next quarterly balance sheet after a +4.4% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Common Stock history
USD · from the balance sheet
- Latest · FY2025
- 45K USD
- Year-over-year change
- +2.3%
- 3-year CAGR
- +146.6%
| Period | Period end | Common Stock | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 45K | +2.3% |
| FY2024 | 2024-12-31 | 44K | +1366.7% |
| FY2023 | 2023-12-31 | 3K | +0.0% |
| FY2022 | 2022-12-31 | 3K | — |
Common Stock vs competitors
How SEPN compares with its peers on the latest reported figures
- SEPN's Sep 2026 common stock of $47K is the 2nd highest of the 7 companies compared; the peer median is $14K.
- Its year-over-year change of +4.4% is the 5th highest of 6, against a peer median of +21.9%.
- Common stock amounts to 0.0% of total assets for SEPN, versus a peer median of 0.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $50K | +13.6% | +32.6% | 0.0% | |
SEPNSepterna, Inc. | Sep 2026 | $47K | +4.4% | +146.6% | 0.0% |
| Mar 2026 | $39K | +21.9% | +13.0% | 0.0% | |
| Jun 2026 | $21K | +23.5% | +175.9% | 0.0% | |
| Mar 2026 | $7K | +75.0% | +32.6% | 0.0% | |
MBXMBX Biosciences, Inc. Common Stock | Sep 2026 | $6K | +0.0% | +81.7% | 0.0% |
KLRAKailera Therapeutics, Inc. | Jun 2026 | $0 | — | — | 0.0% |
| Peer median (excluding SEPN) | $14K | +21.9% | +32.6% | 0.0% | |
Competitors are the stored peer set for SEPN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Septerna, Inc.
NASDAQ:SEPN
Intrinsic Alpha fair value
Locked
Current Price
$39.45
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.